Ally Bridge Group, based in Hong Kong, is a global healthcare-focused investment group founded in 2013. The venture fund invests in various stages from Seed to Series D in companies within the BioTech, Healthcare, Medical Device, and Pharmaceuticals sectors. With a portfolio including companies like Elligo Health Research and Imperative Care, Ally Bridge Group has made 67 investments and has seen 27 exits. The fund, led by Partner Alan Chen, is committed to venture and growth capital, buyout, and hedge fund investing. For more information, visit their website at www.ally-bridge.com.